Aclaris Therapeutics, Inc. (ACRS)
6.52
+0.21
(+3.33%)
USD |
NASDAQ |
Aug 25, 15:30
Aclaris Therapeutics Shareholders Equity (Quarterly) : 124.58M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 124.58M |
| March 31, 2026 | 143.65M |
| December 31, 2025 | 103.08M |
| September 30, 2025 | 120.10M |
| June 30, 2025 | 131.74M |
| March 31, 2025 | 144.07M |
| December 31, 2024 | 155.55M |
| September 30, 2024 | 130.15M |
| June 30, 2024 | 133.82M |
| March 31, 2024 | 142.01M |
| December 31, 2023 | 157.18M |
| September 30, 2023 | 156.33M |
| June 30, 2023 | 179.75M |
| March 31, 2023 | 176.81M |
| December 31, 2022 | 197.62M |
| September 30, 2022 | 219.84M |
| June 30, 2022 | 235.75M |
| March 31, 2022 | 180.20M |
| December 31, 2021 | 197.34M |
| September 30, 2021 | 216.58M |
| June 30, 2021 | 233.82M |
| March 31, 2021 | 112.29M |
| Date | Value |
|---|---|
| December 31, 2020 | 37.65M |
| September 30, 2020 | 40.76M |
| June 30, 2020 | 49.37M |
| March 31, 2020 | 58.18M |
| December 31, 2019 | 69.91M |
| September 30, 2019 | 85.28M |
| June 30, 2019 | 137.23M |
| March 31, 2019 | 182.25M |
| December 31, 2018 | 215.12M |
| September 30, 2018 | 146.33M |
| June 30, 2018 | 174.20M |
| March 31, 2018 | 200.47M |
| December 31, 2017 | 225.26M |
| September 30, 2017 | 244.26M |
| June 30, 2017 | 168.14M |
| March 31, 2017 | 160.29M |
| December 31, 2016 | 169.49M |
| September 30, 2016 | 81.12M |
| June 30, 2016 | 90.24M |
| March 31, 2016 | 83.21M |
| December 31, 2015 | 92.52M |
| September 30, 2015 | 40.19M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Corcept Therapeutics, Inc. | 705.78M |
| Nektar Therapeutics | 903.12M |
| Xeris Biopharma Holdings, Inc. | -9.734M |
| Crinetics Pharmaceuticals, Inc. | 1.192B |
| Alumis, Inc. | 452.16M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 179.69M |
| Total Liabilities (Quarterly) | 55.11M |
| Debt to Equity Ratio | 0.0149 |
| Current Ratio | 3.462 |
| Net Debt Paydown Yield | 0.02% |